Zomedica Posts 35% Q1 Revenue Growth to $8.8M, Significantly Cuts Net Loss
ZOMDF has more than doubled off its 52-week low of $0.035.
Summary
Zomedica Corp. reported strong first-quarter 2026 results, with revenue increasing 35% year-over-year to $8.8 million. Crucially, the company significantly reduced its net loss to $4.6 million for the quarter, a substantial improvement from the $63.8 million net loss in Q1 2025 and the $81.9 million annual loss reported for 2025. This positive performance follows a challenging period that included the company's delisting to OTCQB in March 2025. The reported $47.5 million in cash and equivalents provides robust liquidity. This indicates strong operational improvements and a potential turnaround, which is highly material for a company of its size. Traders will be watching for sustained growth in its diagnostic and consumable segments and continued progress towards profitability.
At the time of this announcement, ZOMDF was trading at $0.09 on OTC in the Life Sciences sector, with a market capitalization of approximately $90.2M. The 52-week trading range was $0.04 to $0.16. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.